| INTANGIBLES |
NOTE 6. INTANGIBLES
The Company’s finite-lived intangible assets consist of acquired intangible assets. The gross carrying amount and accumulated amortization of intangible assets as of September 30, 2022 and December 31, 2021 are summarized as follows:
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
September 30, 2022 |
|
|
Estimated |
|
|
|
|
|
|
|
|
|
|
|
Useful |
|
Gross |
|
|
|
|
|
|
|
|
Lives |
|
Carrying |
|
Accumulated |
|
Intangible |
($'s in thousands) |
|
(Years) |
|
Value |
|
Amortization |
|
Assets, Net |
Amortizable intangible assets: |
|
|
|
|
|
|
|
|
|
|
|
|
Ceracade® |
|
|
3 |
|
$ |
300 |
|
$ |
(300) |
|
$ |
— |
Luxamend® |
|
|
3 |
|
|
50 |
|
|
(50) |
|
|
— |
Targadox® |
|
|
3 |
|
|
1,250 |
|
|
(1,250) |
|
|
— |
Ximino® |
|
|
7 |
|
|
7,134 |
|
|
(3,228) |
|
|
3,906 |
Exelderm® |
|
|
3 |
|
|
1,600 |
|
|
(1,600) |
|
|
— |
Accutane® |
|
|
5 |
|
|
4,727 |
|
|
(1,497) |
|
|
3,230 |
Amzeeq® |
|
|
9 |
|
|
15,162 |
|
|
(1,263) |
|
|
13,899 |
Zilxi® |
|
|
9 |
|
|
3,760 |
|
|
(313) |
|
|
3,447 |
|
|
|
|
|
|
33,983 |
|
|
(9,501) |
|
|
24,482 |
Non-amortizable intangible assets: |
|
|
|
|
|
|
|
|
|
|
|
|
Anti-itch product (1) |
|
|
3 |
|
|
3,942 |
|
|
— |
|
|
3,942 |
Total intangible assets |
|
|
|
|
$ |
37,925 |
|
$ |
(9,501) |
|
$ |
28,424 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
December 31, 2021 |
|
|
Estimated |
|
|
|
|
|
|
|
|
|
|
|
Useful |
|
Gross |
|
|
|
|
|
|
|
Lives |
|
Carrying |
|
Accumulated |
|
Intangible |
($’s in thousands) |
|
(Years) |
|
Value |
|
Amortization |
|
Assets, Net |
Amortizable intangible assets: |
|
|
|
|
|
|
|
|
|
|
|
|
Ceracade® |
|
|
3 |
|
$ |
300 |
|
$ |
(300) |
|
$ |
— |
Luxamend® |
|
|
3 |
|
|
50 |
|
|
(50) |
|
|
— |
Targadox® |
|
|
3 |
|
|
1,250 |
|
|
(1,250) |
|
|
— |
Ximino® |
|
|
7 |
|
|
7,134 |
|
|
(2,463) |
|
|
4,671 |
Exelderm® |
|
|
3 |
|
|
1,600 |
|
|
(1,600) |
|
|
— |
Accutane® |
|
|
5 |
|
|
4,727 |
|
|
(788) |
|
|
3,939 |
|
|
|
|
|
|
15,061 |
|
|
(6,451) |
|
|
8,610 |
Non-amortizable intangible assets: |
|
|
|
|
|
|
|
|
|
|
|
|
Anti-itch product (1) |
|
|
3 |
|
|
3,942 |
|
|
— |
|
|
3,942 |
Total intangible assets |
|
|
|
|
$ |
19,003 |
|
$ |
(6,451) |
|
$ |
12,552 |
(1)The Company is transferring manufacturing to an existing contract manufacturer and upon validation will launch such product and commence amortizing.
The Company’s amortization expense for the three-month periods ended September 30, 2022 and 2021 was $1.0 million and $0.7 million, respectively. The Company’s amortization expense for the nine-month periods ended September 30, 2022 and 2021 was $3.1 million and $2.0 million, respectively. Amortization expense is recorded as a component of cost of goods sold in the Company’s unaudited condensed consolidated statements of operations.
Future amortization of the Company’s intangible assets is as follows:
|
|
|
|
|
|
Total |
($’s in thousands) |
|
Amortization |
Remainder of 2022 |
|
$ |
1,017 |
December 31, 2023 |
|
|
4,067 |
December 31, 2024 |
|
|
4,068 |
December 31, 2025 |
|
|
4,067 |
December 31, 2026 |
|
|
2,855 |
Thereafter |
|
|
8,408 |
Subtotal |
|
$ |
24,482 |
Asset not yet placed in service |
|
|
3,942 |
Total |
|
$ |
28,424 |
|